Could a lower-cost MS therapy match ocrelizumab?

Clinical takeaway: For adults with newly diagnosed relapsing MS and recent disease activity, rituximab may be a reasonable lower-cost alternative to ocrelizumab when clinicians and patients are weighing anti-CD20 therapy options, with attention to infection risk.

Ocrelizumab is approved for relapsing MS, while rituximab is commonly used off-label and is generally less expensive — making head-to-head evidence especially relevant for treatment access and cost-conscious care.

In the phase 3, multicenter, double-blind OVERLORD-MS trial, investigators randomly assigned 218 adults with newly diagnosed relapsing MS to rituximab or ocrelizumab every 6 months for 24 months. Of these, 216 received treatment: 132 in the rituximab group and 84 in the ocrelizumab group.

From month 6 to month 24, 92.2% of patients receiving rituximab had no new or enlarging T2 lesions on MRI, compared with 94.8% of those receiving ocrelizumab — a difference of just 2.6 percentage points, meeting the trial’s prespecified standard for noninferiority.

Relapse rates, disability outcomes, and cognitive-performance profiles were also described as similar between groups. Serious adverse events occurred in 8% of rituximab-treated patients and 7% of ocrelizumab-treated patients. Infections were more frequent with rituximab, reported in 82% of participants versus 69% with ocrelizumab.

The authors concluded that “rituximab was noninferior to ocrelizumab” for suppressing MRI-detected disease activity in this population.

The findings strengthen the evidence base for rituximab, an off-label anti-CD20 therapy, as a potentially cost-saving option in newly diagnosed relapsing MS — while underscoring the need to monitor infections and individualize therapy decisions.

Source: Torkildsen O, et al. (2026 July 1) N Engl J Med. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis